Explore more publications!
Maryland Healthcare Reporter
Got News to Share?

Maryland Healthcare Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on February 20, 2026

'SUCK IT UP, BUTTERCUP,' DOCUMENTARY SETS MARCH 19 BALTIMORE SCREENING TO SPOTLIGHT SYSTEMIC PRESSURES IN U.S. MEDICINE
Feb. 20, 2026

'SUCK IT UP, BUTTERCUP,' DOCUMENTARY SETS MARCH 19 BALTIMORE SCREENING TO SPOTLIGHT SYSTEMIC PRESSURES IN U.S. MEDICINE

Indeterminate EIN Presswire
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Feb. 20, 2026

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Indeterminate GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb. 20, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
Feb. 20, 2026

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Indeterminate GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb. 20, 2026

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Feb. 20, 2026

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Feb. 20, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Indeterminate GlobeNewswire
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Feb. 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Indeterminate GlobeNewswire
Sadhguru Presents Innovative AI Hologram Tech at Massive Event
Feb. 20, 2026

Sadhguru Presents Innovative AI Hologram Tech at Massive Event

Indeterminate GlobeNewswire
NEW HUMAN CLINICAL TRIAL WITH GLUCORAPHANIN-RICH BROCCOLI SEED EXTRACT SHOWS DOUBLING OF SULFORAPHANE BIOAVAILABILITY
Feb. 20, 2026

NEW HUMAN CLINICAL TRIAL WITH GLUCORAPHANIN-RICH BROCCOLI SEED EXTRACT SHOWS DOUBLING OF SULFORAPHANE BIOAVAILABILITY

Indeterminate EIN Presswire
ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting
Feb. 20, 2026

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

Indeterminate GlobeNewswire
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Feb. 20, 2026

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Indeterminate GlobeNewswire
SRx Health Solutions Increases Ownership of Opendoor Technologies by 30% and is Now Net Long Cryptocurrency Holdings
Feb. 20, 2026

SRx Health Solutions Increases Ownership of Opendoor Technologies by 30% and is Now Net Long Cryptocurrency Holdings

Indeterminate GlobeNewswire
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Feb. 20, 2026

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

Indeterminate GlobeNewswire
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
Feb. 20, 2026

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

Indeterminate GlobeNewswire
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Feb. 20, 2026

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions